key: cord-0998708-ddzfvpzn authors: Gutiérrez-Chamorro, Lucía; Riveira-Muñoz, Eva; Barrios, Clara; Palau, Vanesa; Massanella, Marta; Garcia-Vidal, Edurne; Badia, Roger; Pedreño, Sònia; Senserrich, Jordi; Rodríguez, Eva; Clotet, Bonaventura; Cabrera, Cecilia; Mitjà, Oriol; Crespo, Marta; Pascual, Julio; Riera, Marta; Ballana, Ester title: SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients date: 2020-11-19 journal: bioRxiv DOI: 10.1101/2020.11.18.388850 sha: bd0a1e1e230a6bcfa7059cb656cedbd211eff9e4 doc_id: 998708 cord_uid: ddzfvpzn There is an urgent need to elucidate the molecular mechanisms underlying the transmissibility and pathogenesis of SARS-CoV-2. ACE2 is a host ectopeptidase with well-described anti-inflammatory and tissue protective functions and the receptor for the virus. Understanding SARS-CoV-2-ACE2 interaction and the expression of antiviral host genes in early infection phase is crucial for fighting the pandemic. We tested the significance of soluble ACE2 enzymatic activity longitudinally in positive nasopharyngeal swabs at two time points after symptom consultation, along with gene expression profiles of ACE2, its proteases, ADAM17 and TMPRRS2, and interferon-stimulated genes (ISGs), DDX58, CXCL10 and IL-6. Soluble ACE2 activity decreased during infection course, in parallel to ACE2 gene expression. On the contrary, SARS-CoV-2 infection induced expression of the ISG genes in positive SARS-CoV-2 samples at baseline compared to negative control subjects, although this increase wanes with time. These changes positively correlated with viral load. Our results demonstrate the existence of mechanisms by which SARS-CoV-2 suppress ACE2 expression and function casting doubt on the IFN-induced upregulation of the receptor. Moreover, we show that initial intracellular viral sensing and subsequent ISG induction is also rapidly downregulated. Overall, our results offer new insights into ACE2 dynamics and inflammatory response in the human upper respiratory tract that may contribute to understand the early antiviral host response to SARS-CoV-2 infection. Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the COVID-19 disease 1 . SARS-CoV-2 infection is manifested in a wide range of symptoms 2,3 , with the risk for increased disease severity correlating with male sex, advanced age and underlying comorbidities 4, 5 . One of the hallmarks of COVID-19 is a dysregulated antiviral immune response 6, 7 . Interestingly, ACE2 expression is reported to be induced upon exposure to interferon (IFN) 8 , following SARS-CoV-2 infection, in contrast with data from SARS-CoV, where cellular ACE2 expression levels are downregulated by viral infection and linked with the pathogenicity of the virus 9 . SARS-CoV-2 may also antagonize initial viral sensing and IFN responses 10, 11 , although the mechanism is still unknown and the temporal relationship between viral load and host gene expression, has not been explored in vivo. At gene transcription level, shotgun RNA sequencing profiles of nasopharyngeal samples from infected subjects associated IFN stimulated gene (ISGs) expression with viral load, age and sex 12 . In this context, the in-depth analysis of nasopharyngeal samples may help to decipher the intricate processes of SARS-CoV-2 infection and the host immune response. Gathering this information must be crucial to better understand how the initial phase of infection may compromise the disease progression. ACE2 is also known to be a tissue-damage protective factor, due to its monocarboxipeptidase actions on Angiotensin (ANG)-II promoting anti-inflammatory functions through Ang-(1-7) production. These two peptides of the renin angiotensin system (RAS) are involved in the regulation of blood pressure and body fluid homeostasis [13] [14] [15] . ACE2 ectodomain is released from the cell surface by ADAM17 and TMPRSS2 16, 17 carboxipeptidases, being TMPRSS2 also necessary for SARS-CoV-2 viral entry due to its function in the priming of viral S protein 16 . Interestingly, once released, the ectodomain of ACE2 keeps the catalytic activity, which is able to cleave circulating vasoactive peptides 16, 17 . In the context of SARS-CoV-2 infection, it might significantly influence viral spread and pathogenesis, either by limiting new viral infections acting as a soluble decoy or alternatively, by reducing local inflammation due to its tissue protective function. Thus, studies focused on key molecular mechanisms early after SARS-CoV-2 infection are of great value to better decipher the inflammation cascade and immune signalling in the initial phase of the disease. Moreover, the role of IFN in ACE2 expression and shedding should be deeply evaluated because of the important implications in modulating inflammatory cytokines. Here, we evaluated the interplay between ACE2 function and host immune response in nasopharyngeal samples of a cohort of SARS-CoV-2 infected subjects, delineating how viral infection modulates both ACE2 expression and function in vivo, as well as, its relation with immune response and viral load. Because of the central role of ACE2 receptor as the viral entry point, deciphering the ACE2 functional role is critical for the understanding of the pathophysiological changes due to SARS-CoV-2 infection. Indeed, SARS-CoV-2 viral entry might trigger cleavage of ACE2 receptor ectodomain, affecting ACE2 function and systemic release. To gain insight into ACE2 function in viral entry and early infection events, we standardized the measurement of soluble ACE2 enzymatic activity in nasopharyngeal swabs as a surrogate marker of ACE2 function in upper respiratory tract ( Supplementary fig 1) . We observed significant lower ACE2 enzymatic activity levels in nasopharyngeal swabs than in serum samples, but suggesting a potential role of ACE2 activity in the upper respiratory tract in SARS-CoV-2 pathogenesis. Thus, soluble ACE2 activity was measured in a cohort of acute infected SARS-CoV-2 subjects, confirmed by a positive PCR diagnostic test and in a group of uninfected controls, matched by age and sex. Epidemiological and clinical characteristics of the infected subjects included in the study are summarized in Table 1 . SARS-CoV-2 positive subjects were longitudinally followed with a first sample at the time of the recruitment (day 0) and a second nasopharyngeal swab 3 days later. ACE2 activity did not significantly differ in SARS-CoV-2 positive compared to negative subjects, although a trend to a higher activity in SARS-CoV-2 positive samples was observed ( Fig 1A) . Interestingly, ACE2 activity at day 3 was significantly lower than the first sample ( Fig 1A, p-value=0,0048), supporting the idea that ACE2 cleavage and release occurs upon viral entry and its function is not recovered thereafter. When samples were stratified according to sex, ACE2 activity levels were higher in SARS-CoV-2 positive males compared to females, irrespective of the day of sampling (Fig 1B, p-value= 0,0008 and p-value=0,009 for day 0 and 3, respectively), in line with previous reports showing higher plasma ACE2 levels in men 18, 19 . We next explored the temporal relationship of ACE2 gene expression in nasopharyngeal swabs from our cohort of positive and negative SARS-CoV-2 subjects. Surprisingly, ACE2 gene expression was significantly lower in positive SARS-CoV-2 than in negative samples ( Fig 1C) , in contrast to previous reports indicating IFN-dependent upregulation of ACE2 expression upon SARS-CoV-2 infection 8 . Moreover, when comparing ACE2 gene expression longitudinally in positive samples, ACE2 expression showed a significant decrease overtime, following the same trend observed with ACE2 enzymatic activity, suggesting that SARS-CoV-2 is able to downregulate the expression of its receptor. No significant differences in ACE2 gene expression were observed when samples were stratified by sex ( Fig 1D) . SARS-CoV-2 viral load was quantified by RT-qPCR at the same timepoints were ACE2 activity and gene expression were determined, to unravel putative interactions between soluble active ACE2 and SARS-CoV-2 infection. As previously reported, viral load significantly decreased from day 0 to day 3 (mean of 2 log reduction, p-value=6,5x10 -07 , Supplementary fig 2A) , showing a similar reduction to that observed for ACE2 expression and parallel to the trend observed for ACE2 activity. No differences in viral load were identified when data was stratified by sex (Table1 and Supplementary fig 2B) . Interestingly, a significant positive correlation was found between ACE2 activity drop and viral load decrease overtime, i.e., the higher the decrease in viral load, the higher the decrease in soluble active ACE2 (spearman correlation coefficient rho=0.355, p-value=0.0246, Fig 2A) . Indeed, ACE2 gene expression also directly correlated with viral load (spearman correlation coefficient rho=0.352, p-value=0.0259 Fig 2B) , strongly suggesting a direct link between viral entry and ACE2 expression and function. To further explore gene expression modulation induced by SARS-CoV-2 infection, mRNA expression of TMPRSS2 and ADAM17, the proteases able to cleave ACE2 ectodomain, together with distinct ISG genes were also measured. In the case of TMPRSS2 and Interestingly, increased expression of ISGs was associated with higher viral load (Fig 3C) but did not correlate with proteases expression (Supplementary Fig 3) supporting also the idea that SARS-CoV-2 infection is inducing an antiviral response upon viral entry that is afterwards suppressed to facilitate infection spread. In this study, we report changes in expression of SARS-CoV-2 infection-related genes and the enzymatic activity of ACE2 in nasopharyngeal swabs contributing to understand the biology of early viral infection. Overall, our findings show the modulation induced by SARS-CoV-2 on its receptor, ACE2, at gene and soluble level throughout the first week after infection in a cohort of mild COVID-19 subjects. This modulation seems to be independent of the ISGs induced upon SARS-CoV-2 infection, also demonstrating that ACE2 expression is not regulated by IFN. Moreover, we show that initial upregulation of antiviral immune response is directly linked to viral load and its upregulation is rapidly reversed within days during the course of infection. Our data adds key relevant knowledge to the understanding of the early antiviral host response to SARS-CoV-2 infection at the site of viral infection. Soluble ACE2 has been described as a risk factor of death or cardiovascular events associated to several kidney or heart diseases [20] [21] [22] [23] , and more recently, also reported in general population 19 . The role of the circulating molecule has been discussed as a feedback pathway to counterbalance the RAS and hyperinflammation activation. In our study, this scenario is also plausible in the upper airway epithelium where viral entry starts to induce the inflammatory cascade that may ultimately lead to the cytokine storm 24 . Upon infection, soluble ACE2 detection in nasopharyngeal swabs shows a slight increase in enzymatic activity, probably due to the infection itself and/or the activity of ADAM17 and/or TMPRS22 sheddases 16 Nasopharyngeal swabs were obtained from 40 patients recruited under the BCN PEP CoV-2 Study (NCT04304053) during the spring SARS-CoV-2 outbreak, in Catalonia (North-East Spain). All COVID-19 cases included in the present analysis were nonhospitalized adults (i.e., ≥ 18 years of age) with quantitative PCR result available at baseline and mild symptom onset who met the diagnostic criteria for COVID-19 (fever, or acute cough, or sudden olfactory or gustatory loss, or rhinitis). Two nasopharyngeal swabs were obtained, at the time of recruitment (day 0) and at follow-up, 3 days after (day 3). Full details of the original study are reported elsewhere 32 . Similarly, a group of COVID-19 negative nasopharyngeal swabs (n=20) were collected following the same procedure and matched by age and sex to the infected patients (mean age: 39 years and 70% females). All negative samples were tested for SARS-CoV-2 infection by PCR with a negative result. The study protocol was approved by the institutional review board of Hospital Germans Trias i Pujol. All participants provided written informed consent. The ACE2 fluorescent enzymatic assay protocol was performed as previously Given that the normality was not fulfilled by the majority of variables, non-parametric methods were applied. Between group differences were evaluated trough Mann-Whitney U test. Wilcoxon signed-rank test was used to evaluate statistically significant changes in paired samples within the SARS-CoV-2 positive cohort (baseline-3 days). Correlation between variables were evaluated through Spearman's rank correlation coefficients. Results were considered as statistically significant at p-value<0.05. Statistical analysis was performed using STATA 15.1. Research COVID-19 situation update worldwide, as of 15 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Asymptomatic cases in a family cluster with SARS-CoV-2 infection Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical and immunological features of severe and moderate coronavirus disease 2019 SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase Not just angiotensinases: New roles for the angiotensin-converting enzymes SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor A pneumonia outbreak associated with a new coronavirus of probable bat origin Circulating plasma concentrations of angiotensin-converting enzyme 2 inmen and women with heart failure and effects of renin-angiotensinaldosterone inhibitors Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical Outcomes Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe Myocardial Fibrosis Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis Angiotensin-converting enzyme 2 protects from severe acute lung failure Replication-dependent downregulation of cellular angiotensinconverting enzyme 2 protein expression by human coronavirus NL63 Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor Factors associated with COVID-19-related death using OpenSAFELY The renin-angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications Human recombinant soluble ACE2 in severe COVID-19 Human coronavirus: Host-pathogen interaction A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and 1 Disease 2. medRxiv This research was supported by the crowdfunding campaign JoEmCorono The authors declare that they have no conflict of interest.